Last reviewed · How we verify
CoronaVac
At a glance
| Generic name | CoronaVac |
|---|---|
| Also known as | Inactivated SARS-CoV-2 Vaccine (Vero Cells) - Sinovac |
| Sponsor | University of Sao Paulo General Hospital |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV) (PHASE2)
- Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine (PHASE4)
- Community-based Sero-epidemiological Study of COVID-19
- Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study
- Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older (PHASE3)
- Immunogenicity Induced by COVID-19 Vaccines in Mexican Population
- Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CoronaVac CI brief — competitive landscape report
- CoronaVac updates RSS · CI watch RSS
- University of Sao Paulo General Hospital portfolio CI